Who
Adrian Adams
Director
Company insider
Files Form 4 as: Director, Talphera; Director, Akebia Therapeutics; COB, CEO and President, Impel Pharmaceuticals; Chief Executive Officer, Aralez Pharmaceuticals; Chief Executive Officer, Pozen Inc /nc; CEO and President, Auxilium Pharmaceuticals; Director, Amylin Pharmaceuticals; CEO, Chairman of the Board, Neurologix Inc/de.
In numbers
- Trades disclosed
- 143
- Buys
- 11
- Sells
- 1
- Bought
- $10.2M
- Sold
- $1.4M
- Companies
- 12
- Companies where not an officer
- 4
- First trade
- 26 Jan 2006
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | TLPH TalpheraBiotechnology | SEC FORM 4 Code A | —5,100 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | TLPH TalpheraBiotechnology | SEC FORM 4 Code A | —5,100 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,600 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,600 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 23 Oct 2025filed 24 Oct 2025 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,600 at $0.00 | filing |
| 23 Oct 2025filed 24 Oct 2025 | TLPH TalpheraBiotechnology | SEC FORM 4 Code A | —4,267 at $0.00 | filing |
| 10 Jun 2025filed 11 Jun 2025 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,600 at $0.00 | filing |
| 10 Jun 2025filed 11 Jun 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 24 Jun 2024filed 24 Jun 2024 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,044 at $0.00 | filing |
| 24 Jun 2024filed 24 Jun 2024 | TLPH TalpheraBiotechnology | SEC FORM 4 Code A | —2,174 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 10 Oct 2023filed 13 Dec 2023 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,487 at $0.00 | filing |
| 10 Oct 2023filed 13 Dec 2023 | TLPH TalpheraBiotechnology | SEC FORM 4 Code A | —581 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
News
Analyzing Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR)AKBA · tickerreport.com · 18 Oct 2026Evolus (NASDAQ:EOLS) & Talphera (NASDAQ:TLPH) Financial ComparisonTLPH · dailypolitical.com · 13 Oct 2026Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumAKBA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Adrian Adams; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.